Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rein Therapeutics, a clinical-stage biotech focused on orphan pulmonary and fibrosis diseases, has closed an underwritten public offering raising $57.5 million. Proceeds will fully fund the ongoing Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis (IPF), support ongoing clinical and regulatory activities, and extend operational cash runway i…